Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
Jordan J. Feld(University Health Network), Barry Bernstein(AbbVie (United States)), Barbara DaSilva-Tillmann(AbbVie (United States)), Ola Weiland(Karolinska University Hospital), Lois Larsen(AbbVie (United States)), Samuel H. Sigal(New York University), David R. Nelson(Harvard University Press), Dorothy H. Crawford(Gallipoli Medical Research Foundation), Kris V. Kowdley(Liver Institute Northwest), Junyuan Xiong(AbbVie (United States)), Eoin Coakley(AbbVie (United States)), Humberto Aguilar, Thomas Podsadecki(AbbVie (United States))
Cited by 907
Related Papers
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
|New England Journal of Medicine|2010|3.3k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
|The Lancet|2014|2.2k
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k